Bionano Genomics Inc Financials
Bionano Genomics Inc (BNGO) reported $28.5M in revenue for fiscal year 2025, down 7.4% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 9 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
A cost-and-margin reset sharply reduced accounting losses and cash burn, but external financing still carried FY2025 liquidity.
From FY2024 to FY2025, gross margin jumped from1.2% to46.3% even as revenue fell. At the same time, operating cash burn narrowed from-$68.9M to-$16.3M , pointing to a cost-structure reset and better unit economics rather than a sales-led recovery or simple scale benefit.
The current ratio improved to 2.0x, but cash on hand was only
The balance sheet looks less strained than a year earlier because total liabilities fell from
Financial Health Signals
Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Bionano Genomics Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Bionano Genomics Inc scores -14.14, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($14.1M) relative to total liabilities ($29.2M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Bionano Genomics Inc passes 4 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 2 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, 1 of 2 efficiency signals pass.
Bionano Genomics Inc reported a net loss of $26.4M while operations used $16.3M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
Bionano Genomics Inc generated $28.5M in revenue in fiscal year 2025. This represents a decrease of 7.4% from the prior year.
Bionano Genomics Inc's EBITDA was -$23.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 73.5% from the prior year.
Bionano Genomics Inc reported -$26.4M in net income in fiscal year 2025. This represents an increase of 76.4% from the prior year.
Bionano Genomics Inc earned -$4.85 per diluted share (EPS) in fiscal year 2025.
Cash & Balance Sheet
Bionano Genomics Inc held $3.0M in cash as of fiscal year 2025; long-term debt is not reported for that period.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Margins & Returns
Bionano Genomics Inc's gross margin was 46.3% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is up 45.0 percentage points from the prior year.
Bionano Genomics Inc's net profit margin was -92.6% in fiscal year 2025, showing the share of revenue converted to profit. No change is given against fiscal year 2024: its reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Bionano Genomics Inc's ROE was -59.4% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 257.2 percentage points from the prior year.
Not shown for fiscal year 2025: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Capital Allocation
Bionano Genomics Inc invested $11.4M in research and development in fiscal year 2025. This represents a decrease of 54.1% from the prior year.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
BNGO Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $30.2M | $28.5M-7.4% | $30.8M-14.8% | $36.1M+29.9% | $27.8M+54.6% | $18.0M+111.5% | $8.5M-16.1% | $10.1M-15.6% | $12.0M+26.3% | $9.5M |
| Cost of Revenue | $15.8M | $15.3M-49.6% | $30.4M+14.5% | $26.6M+21.5% | $21.9M+54.9% | $14.1M+146.2% | $5.7M-15.3% | $6.8M-22.3% | $8.7M+44.5% | $6.0M |
| Gross Profit | $14.3M | $13.2M+3369.7% | $380K-96.0% | $9.6M+60.9% | $5.9M+53.5% | $3.9M+39.7% | $2.8M-17.5% | $3.4M+2.2% | $3.3M-5.3% | $3.5M |
| R&D Expenses | $12.2M | $11.4M-54.1% | $24.8M-54.1% | $54.0M+10.2% | $49.0M+118.1% | $22.5M+119.2% | $10.3M+12.9% | $9.1M-4.3% | $9.5M-21.0% | $12.0M |
| SG&A Expenses | $34.3M | $35.1M-32.2% | $51.9M-44.1% | $92.8M+4.7% | $88.6M+51.5% | $58.5M+88.3% | $31.1M+54.1% | $20.2M+41.7% | $14.2M+1.0% | $14.1M |
| Operating Income | -$32.2M | -$33.3M+67.9% | -$104.0M+51.7% | -$215.2M-63.4% | -$131.7M-70.8% | -$77.1M-100.0% | -$38.6M-49.0% | -$25.9M-26.7% | -$20.4M+12.1% | -$23.2M |
| Interest Expense | N/A | N/A | N/A | $5.1M+1617.8% | $298K-67.9% | $927K-63.2% | $2.5M+10.2% | $2.3M+65.5% | $1.4M+133.7% | $591K |
| Income Tax | $67K | $67K+103.0% | $33K-46.8% | $62K-96.7% | $1.9M+133.0% | -$5.7M-19813.8% | $29K+37.8% | $21K+35.7% | $16K-16.4% | $19K |
| Net Income | -$32.2M | -$26.4M+76.4% | -$112.0M+51.8% | -$232.5M-75.3% | -$132.6M-83.1% | -$72.4M-76.2% | -$41.1M-37.9% | -$29.8M-61.2% | -$18.5M+20.8% | -$23.4M |
| EPS (Diluted) | — | -$4.85 | -$88.13 | -$408.60 | -$4.58 | -$0.26 | N/A | N/A | N/A | N/A |
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
BNGO Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 |
|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $73.6M-4.0% | $76.7M-64.2% | $214.4M-30.3% | $307.5M-18.5% | $377.1M+523.8% | $60.5M+100.1% | $30.2M+21.8% | $24.8M+144.5% | $10.1M |
| Current Assets | $45.4M+14.9% | $39.5M-71.8% | $140.1M-10.9% | $157.3M-42.3% | $272.4M+482.2% | $46.8M+65.6% | $28.3M+22.7% | $23.0M+222.5% | $7.1M |
| Cash & Equivalents | $3.0M-67.4% | $9.2M-48.9% | $17.9M+252.5% | $5.1M-79.3% | $24.6M-36.1% | $38.4M+122.1% | $17.3M+4.8% | $16.5M+1516.9% | $1.0M |
| Inventory | $7.8M-41.0% | $13.3M-51.9% | $27.6M-7.3% | $29.8M+140.3% | $12.4M+273.7% | $3.3M-3.7% | $3.4M+222.3% | $1.1M-36.9% | $1.7M |
| Accounts Receivable | $5.2M+9.4% | $4.8M-49.0% | $9.3M+32.7% | $7.0M+42.3% | $4.9M+77.8% | $2.8M-56.2% | $6.3M+40.3% | $4.5M+34.7% | $3.4M |
| Goodwill | N/A | N/A | $0-100.0% | $77.3M+37.6% | $56.2M+682.9% | $7.2M | $0 | N/A | N/A |
| Total Liabilities | $29.2M-29.4% | $41.3M-65.1% | $118.2M+103.5% | $58.1M+45.3% | $40.0M+57.6% | $25.4M-4.6% | $26.6M+81.3% | $14.7M-75.7% | $60.4M |
| Current Liabilities | $22.9M-38.6% | $37.3M-62.7% | $100.0M+178.8% | $35.9M+64.3% | $21.8M+144.2% | $8.9M-66.1% | $26.4M+483.0% | $4.5M-72.8% | $16.7M |
| Long-Term Debt | N/A | N/A | N/A | N/A | $0-100.0% | $16.3M | $0-100.0% | $9.0M | $0 |
| Total Equity | $44.4M+25.6% | $35.4M-63.2% | $96.2M-61.4% | $249.4M-26.0% | $337.1M+860.9% | $35.1M+871.0% | $3.6M-64.4% | $10.1M+120.2% | -$50.2M |
| Retained Earnings | -$719.6M-3.8% | -$693.2M-19.3% | -$581.2M-66.7% | -$348.7M-61.4% | -$216.1M-50.4% | -$143.7M-40.1% | -$102.6M-41.0% | -$72.8M-34.1% | -$54.3M |
BNGO Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$20.5M | -$16.3M+76.3% | -$68.9M+44.9% | -$125.2M-0.3% | -$124.8M-73.5% | -$71.9M-87.7% | -$38.3M-29.7% | -$29.5M-48.1% | -$19.9M+4.2% | -$20.8M |
| Capital Expenditures | N/A | N/A | N/A | N/A | N/A | N/A | $0-100.0% | $61K-81.6% | $332K-67.4% | $1.0M |
| Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | -$38.3M-29.5% | -$29.6M-45.9% | -$20.3M+7.1% | -$21.8M |
| Investing Cash Flow | $18.5M | -$12.7M-117.3% | $73.8M+205.7% | $24.2M-70.8% | $82.8M+129.8% | -$278.1M-11249.5% | -$2.5M-3912.7% | -$61K+81.6% | -$332K+67.4% | -$1.0M |
| Financing Cash Flow | $2.6M | $24.0M+275.7% | -$13.7M-112.0% | $113.8M+394.7% | $23.0M-93.2% | $336.1M+443.0% | $61.9M+103.8% | $30.4M-15.1% | $35.8M+103.2% | $17.6M |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
BNGO Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 |
|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 46.3%+45.0pp | 1.2%-25.3pp | 26.5%+5.1pp | 21.4%-0.2pp | 21.5%-11.1pp | 32.6%-0.6pp | 33.2%+5.8pp | 27.4%-9.1pp | 36.5% |
| Operating Margin | -117.0% | -337.9% | -596.0% | -473.7% | -428.8% | -453.4% | -255.4% | -170.1% | -244.3% |
| Net Margin | -92.6% | -364.0% | -643.7% | -476.9% | -402.8% | -483.4% | -294.3% | -154.1% | -245.8% |
| Return on Equity | -59.4%+257.2pp | -316.7%-74.9pp | -241.8%-188.6pp | -53.2%-31.7pp | -21.5%+95.7pp | -117.2%+708.1pp | -825.2%-642.8pp | -182.5% | N/A |
| Return on Assets | -35.9%+110.2pp | -146.1%-37.7pp | -108.4%-65.3pp | -43.1%-23.9pp | -19.2%+48.8pp | -68.0%+30.7pp | -98.7%-24.1pp | -74.6%+155.7pp | -230.3% |
| Current Ratio | 1.98+0.9x | 1.06-0.3x | 1.40-3.0x | 4.38-8.1x | 12.47+7.2x | 5.23+4.2x | 1.07-4.0x | 5.09+4.7x | 0.43 |
| Debt-to-Equity | 0.66-0.5x | 1.17-0.1x | 1.23+1.0x | 0.23+0.2x | 0.00-0.5x | 0.47+0.5x | 0.00-0.9x | 0.89 | N/A |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | -450.6% | -292.1% | -168.9% | -229.7% |
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.
Similar Companies
Where Bionano Genomics Inc Ranks
Frequently Asked Questions
What is Bionano Genomics Inc's annual revenue?
Bionano Genomics Inc (BNGO) reported $28.5M in total revenue for fiscal year 2025. This represents a -7.4% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Bionano Genomics Inc's revenue growing?
Bionano Genomics Inc (BNGO) revenue declined by 7.4% year-over-year, from $30.8M to $28.5M in fiscal year 2025.
Is Bionano Genomics Inc profitable?
No, Bionano Genomics Inc (BNGO) reported a net income of -$26.4M in fiscal year 2025, with a net profit margin of -92.6%.
What is Bionano Genomics Inc's EBITDA?
Bionano Genomics Inc (BNGO) had EBITDA of -$23.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Bionano Genomics Inc's gross margin?
Bionano Genomics Inc (BNGO) had a gross margin of 46.3% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Bionano Genomics Inc's net profit margin?
Bionano Genomics Inc (BNGO) had a net profit margin of -92.6% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Bionano Genomics Inc's return on equity (ROE)?
Bionano Genomics Inc (BNGO) has a return on equity of -59.4% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Bionano Genomics Inc's operating cash flow?
Bionano Genomics Inc (BNGO) recorded an outflow of $16.3M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Bionano Genomics Inc's total assets?
Bionano Genomics Inc (BNGO) had $73.6M in total assets as of fiscal year 2025, including both current and long-term assets.
How much does Bionano Genomics Inc spend on research and development?
Bionano Genomics Inc (BNGO) invested $11.4M in research and development during fiscal year 2025.
What is Bionano Genomics Inc's current ratio?
Bionano Genomics Inc (BNGO) had a current ratio of 1.98 as of fiscal year 2025, which is generally considered healthy.
What is Bionano Genomics Inc's debt-to-equity ratio?
Bionano Genomics Inc (BNGO) had a debt-to-equity ratio of 0.66 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Bionano Genomics Inc's return on assets (ROA)?
Bionano Genomics Inc (BNGO) had a return on assets of -35.9% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Bionano Genomics Inc's cash runway?
Based on fiscal year 2025 data, Bionano Genomics Inc (BNGO) had $3.0M in cash against an annual operating cash burn of $16.3M. This gives an estimated cash runway of approximately 2 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Bionano Genomics Inc's Altman Z-Score?
Bionano Genomics Inc (BNGO) has an Altman Z-Score of -14.14, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Bionano Genomics Inc's Piotroski F-Score?
Bionano Genomics Inc (BNGO) has a Piotroski F-Score of 4 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Bionano Genomics Inc's earnings high quality?
Bionano Genomics Inc (BNGO) reported a net loss of $26.4M while operations used $16.3M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Bionano Genomics Inc?
Bionano Genomics Inc (BNGO) scores 34 out of 100 on our Financial Health Score, indicating weak standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.